Innovating Health Against Future Pandemics
- 1st Edition - April 30, 2024
- Editors: Simona Mellino, Enrico Santus, Antonella Santuccione Chadha, Dario Motti
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 6 8 1 - 8
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 6 8 2 - 5
Innovating Health Against Future Pandemics covers the key aspects which drive heterogeneity in an individual's response to COVID-19, including age, sex, genetic makeup, immune re… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteInnovating Health Against Future Pandemics covers the key aspects which drive heterogeneity in an individual's response to COVID-19, including age, sex, genetic makeup, immune responses, comorbidities, and viral strains/loads. This book also reviews the case examples from other disciplines to highlight areas where precision medicine and AI could be applied for the improvement of pandemic management. This includes research, primary and secondary prevention, isolation/tracking, hospitalization and patient management, diagnosis, and treatments. Lastly, drawing on past experiences for each of the areas this book provides practical recommendations to manage future pandemics.
COVID-19 offered an unprecedented occasion to test the impact of digitally enabled solutions within precision medicine for public health and for accelerating their deployment and adoption.
- Explores the benefits of AI technologies in triage, diagnosis, and risk prediction
- Reviews the innovative clinical trial designs in terms of platforms and decentralization
- Covers Healthcare workload, including remote monitoring to help prevent burnout
Researchers, advanced graduate students, and clinicians in the fields of neuroscience, psychiatry, biomedicine, and computer science
- Cover image
- Title page
- Table of Contents
- About the WBP book series
- Copyright
- Dedication
- Editor’s biographies
- Foreword
- Acknowledgments
- Introduction
- 1. Introduction: Healthcare Innovation to prevent and manage future outbreaks effectively
- 2. The Women's Brain Project contribution: From neurology to healthcare innovation
- 3. Organization and scope of this book
- Section 1. Epidemiology, data, and technology
- Chapter 1. Advancing epidemiological understanding: Navigating challenges and embracing innovations in the age of technology and data
- 1. Introduction: Epidemiology, data, and technology
- 2. Data and technology
- 3. Pitfalls (challenges and biases)
- 4. A future model
- 5. Conclusion
- Section 2. Treatment/pharmaceutical R&D
- Chapter 2. The use of computational biology in protein engineering and drug discovery
- 1. Introduction
- 2. Methodology of the search
- 3. Target identification for drug discovery
- 4. Protein engineering through algorithms
- 5. De novo drug design toward personalized medicine
- 6. Ligand-based modeling
- 7. Molecular docking
- 8. QSAR modeling
- 9. Clinical translation
- 10. Conclusion
- Chapter 3. Innovative clinical trial design and operation—Implementing hybrid and fully decentralized clinical trials in a post-COVID world
- 1. Introduction
- 2. Adoption and reach
- 3. Decentralized trial planning and preparation
- 4. Hybrid trials
- 5. Fully decentralized clinical trials
- 6. Trial enablement
- 7. Conclusion and recommendations
- Section 3. Triage, diagnosis, risk prediction
- Chapter 4. A perspective on Artificial Intelligence for digital pharmacovigilance in pandemics
- 1. Introduction
- 2. Traditional pharmacovigilance
- 3. Artificial Intelligence for traditional pharmacovigilance
- 4. Social media listening for digital pharmacovigilance
- 5. A case study: An NLP system for ADE detection on social media
- 6. Conclusions
- Chapter 5. Consequences of the isolation in vulnerable populations: Brain and mental health in the older population
- 1. Introduction
- 2. The effects of social isolation on mental and brain health among the older population
- 3. The effects of social isolation on mental and brain health among vulnerable sub-populations
- 4. Measures and interventions for social isolation and loneliness and actionable recommendations for the future
- 5. Conclusion
- Chapter 6. Design for isolation, confinement, and mental health during intensive care
- 1. Observations about intensive care units during COVID-19
- 2. Design for isolation and confinement
- 3. Lessons learned from astronauts training facilities
- 4. Technological and architectural solutions for ICU
- 5. Conclusions
- Chapter 7. Triage, diagnosis and risk prediction: The benefits and challenges of digital health and AI technologies
- 1. Introduction
- 2. From prevention and early diagnose to remote monitoring
- 3. Challenges for development and scale up
- 4. Outlook and recommendations
- Section 4. Management and policies
- Chapter 8. How digital solutions can ensure continued high-quality care for patients during pandemics
- 1. Introduction
- 2. Key challenges faced by patients with chronic and serious diseases during a pandemic
- 3. How digital health solutions can help ensure continuous, quality care for those with chronic and serious health conditions
- 4. How digital solutions can contribute to population health management during a pandemic?
- 5. Outlook and recommendations
- Chapter 9. Beyond one-size-fits-all: Precision medicine and novel technologies for sex- and gender-inclusive COVID-19 pandemic management
- 1. Introduction
- 2. The role of new technologies in sex- and gender-sensitive precision medicine
- 3. Pandemic management and novel technologies: A sex and gender approach
- 4. What have we learned from COVID-19? Call for action
- Chapter 10. Future outlook
- 1. A launchpad for healthcare innovations in uncharted waters
- 2. The next big one
- 3. Gearing up for the future
- Index
- No. of pages: 300
- Language: English
- Edition: 1
- Published: April 30, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443136818
- eBook ISBN: 9780443136825
SM
Simona Mellino
Simona Mellino is Strategy and Business Enablement Lead at Roche Pharma, managing portfolio strategy and management. Prior to that, she was a Life Sciences Consultant, advising top pharmaceutical and medtech companies on commercial and digital strategies and focused on precision medicine in oncology and neurology. She worked at Accenture in the Life Sciences Strategy and Consulting practice. She has 8 years of experience in product development and launch across pharmaceuticals, medical devices, digital health categories and author of several publications in precision medicine (e.g., Nature Digital Medicine). She serves as Vice President of Women’s Brain Project, where she works on novel technologies for brain and mental health. She holds a Ph.D. in Computational Chemistry from Oxford University and a Master in Healthcare Management, Economics and Policy from SDA Bocconi with a specialization in market access and pricing.
ES
Enrico Santus
Enrico Santus is Head of Human Computation in the CTO Office at Bloomberg, where he manages products and designs the long-term vision for human-machine interactions. In the last decade, he has been at the forefront of AI, developing and leading Microsoft products in Machine Learning (ML) and Natural Language Processing (NLP). His education includes a PhD in NLP at The Hong Kong Polytechnic University on topics related to lexical semantics and ontology generation. After the PhD, he pursued three years of postdoctoral research between the SUTD and the CSAIL (MIT), actively contributing to the development and industrialization of AI solutions for medicine, pharma & crop science, as well as numerous COVID-19 initiatives, including the MIT tracing app. He was granted several awards (e.g., Stand Up to Cancer, Facebook, etc.) for his research, which counts over 75 papers and 1500 citations. He is advisor of several start-ups and has been an invited speaker on NLP at the White House. In the last years, he co-authored several fact-sheets for the US Congress and other regulators.
AS
Antonella Santuccione Chadha
Dr. Chadha is a highly accomplished medical expert renowned for her work in neuroscience, neurological disorders, and psychiatric diseases. She co-founded and serves as the pro-bono CEO of the Women's Brain Project and is also the Vice-President at Euresearch. Recognized as a transformative leader and startup revitalizer, she has provided strategic guidance to CEOs, boards of directors, and junior colleagues. Her extensive career includes regulatory work at the Swiss Agency for Therapeutic Products and executive roles at Roche Diagnostic, Roche Pharmaceutical, and Biogen. She has even held the position of Chief Medical Officer and ad-interim CEO at Altoida.
Dr. Chadha has always been dedicated to solving the mysteries surrounding Alzheimer's and psychiatric conditions. Her research at the University of Zurich focused on immunotherapies for neurodegenerative disorders, contributing to the development of the first Alzheimer's disease-modifying treatment.
Her accomplishments have earned her numerous accolades, including being listed among Switzerland's Top 100 Women in Business since 2018 and being named Woman of the Year in Switzerland in 2019. She's received the World Sustainability Award for her contributions to Precision Medicine and the "Premio Medicina Italia" for her pandemic management efforts. In 2021, she was nominated among the top 10 innovative women in Switzerland, and in 2022, she received the Veuve Clicquot Bold Woman Award, followed by the “Dean Martin” International Prize in 2023.
Dr. Chadha is passionate about eliminating bias in clinical development, aiming to achieve precision medicine. She advocates for the establishment of the first global sex and gender precision medicine research institute, based in Switzerland.
Beyond her professional achievements, Dr. Chadha is an author with contributions to scientific publications, TEDx talks, and books, including "Sex and Gender Differences in Alzheimer's Disease" and "Una Bambina Senza Testa”.
DM
Dario Motti
Dario Motti is a Team leader and Senior Consultant at Confinis AG, a global medtech consulting firm for medtech innovation. He has a PhD in Neuroscience and over 15 years of experience in pre-clinical and clinical research in academic and private organizations across multiple continents and countries. Over the course of his career, Dario worked on a diverse range of topics from genomics to gene therapy to drug development to digital biomarker, both for academic organizations and industry. He dedicated the last 7 years to the digital medicine space, supporting product teams in designing and executing regulatory and clinical strategy to deliver effective, beneficial, and impactful medical devices to patients and care teams worldwide. His experience, spans all aspects of digital health: over the years, he participated in and led the development, validation and commercialization of a diverse range of regulated digital products including Digital Endpoints, Digital Therapeutics (DTx), Remote Patients Monitoring solutions (RPMs), Clinical Decision Support tools and algorithms. He has an extensive publication record and has been an invited speaker at conferences in Europe, US and Japan.